Effective management of N-nitrosamines associated with leachables from packaging systems

A great article by @AndyT for Pharmaceutical Manufacturing and Packing Sourcer (PMPS). It examines how packaging systems can contribute to N-nitrosamine impurities in pharmaceutical products and why identifying these risks requires the right testing strategy.

Drawing on examples involving blister packaging and large-volume parenterals, Andrew explores potential sources of leachable nitrosamines and the role of targeted extractables and leachables testing in identifying and managing these risks.

Read the full article to learn more about the considerations for assessing N-nitrosamines associated with pharmaceutical packaging here: https://www.calameo.com/read/0061133859a6505529874?page=131

6 Likes

The targeted analysis is a real key component to this. The non-targeted analysis that is traditionally used in E&L studies is unlikely to have the sensitivity needed for nitrosamines.

2 Likes

Oh, it looks like the nitrosamine contamination issue is far from over. :fearful: :fearful: :fearful:

2 Likes

Let the fun continue…

1 Like

Thank you for sharing. This is really interesting and also troubling. As more questions arise in the course of E&L evaluation/analytics which need to be covered. Or at least should be taken into consideration.

Maybe a contreversial comment/question at this point:

I wonder how far the analytical expert should go to cover every possibility or should this expert start arguing and taking a more risk-based approach (still evidence based) to show “authorities” alternative approaches based on plausibility, expertise, common sense/knowledge.

Your thoughts?

1 Like

I think this right here is the primary problem in E&L today. If we really think about it, everything is risk based, especially when there are a lot of unknowns. I’ve said frequently that if we wanted to be 0 risk in our QC testing, we would test literally every tablet manufactured and never have a product. We’re relying on a risk assessment to say that our sample is representative. That risk assessment is based on sound science and standardized expectations.

In E&L there are not enough standardized expectations. So, the level of exploration and scientific rigor varies wildly. Somewhat separately, we see drastically different results in round-robin studies.

1 Like

A topic for the new E&L section of the forthcoming USP Exchange??

Stay posted for more information on the launch of the new site.

4 Likes

Yes! And there are a few E&L experts already on tap to join.

3 Likes